News Agency
The Times

China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke

  • Written by PR Newswire

NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been approved for marketing by the National Medical Products Administration. This product is indicated for the...

Read more: China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic...

How Can Businesses Reduce the Risk of Commercial Litigation?

Commercial disputes often begin with a misunderstanding, an unclear contract or a delayed response to a growing problem. Seeking early advice from Litigation Lawyers Sydney with PCL lawyers can help businesses trust and identify legal risks, clarify obligations and create a strategy... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion